SLM6031434

SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC50 value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO) -induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) [1][2].

Product Specifications

CAS Number

[1897379-33-7]

UNSPSC

12352005

Target

SphK

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/slm6031434.html

Smiles

N=C(N1[C@H](C2=NC(C3=CC=C(OCCCCCCCC)C(C(F)(F)F)=C3)=NO2)CCC1)N

Molecular Formula

C22H30F3N5O2

Molecular Weight

453.50

References & Citations

[1]Schwalm S, et al. Validation of highly selective sphingosine kinase 2 inhibitors SLM6031434 and HWG-35D as effective anti-fibrotic treatment options in a mouse model of tubulointerstitial fibrosis. Cell Signal. 2021 Mar;79:109881. |[2]Imeri F, et al. Loss of sphingosine kinase 2 enhances Wilm's tumor suppressor gene 1 and nephrin expression in podocytes and protects from streptozotocin-induced podocytopathy and albuminuria in mice. Matrix Biol. 2021 Apr;98:32-48.